Discovery of IL-18 as a Protein Linked to Doxorubicin Resistance in Breast Cancer
Author Information
Author(s): Yao Ling, Zhang Yan, Chen Keying, Hu Xiaofang, Xu Lisa X.
Primary Institution: School of Biomedical Engineering and Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, China
Hypothesis
Secreted proteins may play important roles in chemoresistance in breast cancer.
Conclusion
The study identified novel secreted proteins related to chemotherapy resistance, with IL-18 confirmed to contribute to doxorubicin resistance.
Supporting Evidence
- 89 differentially expressed secreted proteins were identified between MCF-7 and MCF-7/Dox.
- IL-18 was validated to contribute to doxorubicin resistance.
- 57 of the identified proteins were novel in relation to doxorubicin resistance.
Takeaway
Researchers found a protein called IL-18 that helps breast cancer cells resist a common chemotherapy drug, doxorubicin.
Methodology
Proteomic strategy using one-dimensional gel electrophoresis followed by liquid chromatography-tandem mass spectrometry to compare secretomes.
Limitations
The study primarily focused on in vitro models and may not fully represent in vivo conditions.
Participant Demographics
Breast cancer patients receiving neoadjuvant chemotherapy.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website